Prof. Mohamed Mabed

Email: mohmabed@mans.edu.eg

Qualifications

Publications(Selected)

1. Mabed M, Shahin, “Mesenchymal Stem Cell-based therapy for the Treatment of Type 1 Diabetes Mellitus.” Curr Stem Cell Res Ther Oct 2011 (In press).
2. Mabed M, “The Potential Utility of Bone Marrow or Umbilical Cord Blood Transplantation For The Treatment of Type I Diabetes Mellitus,” Biol Blood Marrow Transplant, vol 17, No. 4, pp 455-64, Apr 2011.
3. Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T, “ A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma” European Journal of Cancer Care, vol 18, No. 5, pp 492-9, sep 2009.
4. Mabed M, Shamaa S, “High-dose chemotherapy plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed Hodgkin disease” Biol Blood Marrow Transplant, Vol 12, No. 9, pp 942-8, Sep 2006.
5. Mabed M, Al-Kgodary T, “Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas” Bone Marrow Transplant, vol 37, No. 8, pp 739-43, Apr 2006.
6. Aref S, Mabed M, El-Sherbiny M,Selim T, Metwaly A, “Cyclin D1 expression in acute leukemia” Hematology, vol 11, No. 1, pp 31-4, Feb 2006.
7. Mabed M, Coffe C, Racadot E, Angonin R, Pavey JJ, Tiberghien P, Herve P, “Differential sensitivity of T lymphocytes and hematopoietic precursor cells to photochemotherapy with 8-methoxypsoralen and ultraviolet A light” Ann Hematol, vol 85, No. 1, pp 17-24, Jan 2006.
8. Mabed M, Maroof S, Zalta K, El-Awadee M, “Delayed or delayed sequential bone marrow transplantation: relevance for acute graft-versus-host disease prevention after major H2 incompatible transplantation” Bone Marrow Transplant, vol 35, No. 8, pp 803-6, Apr 2005
9. Mabed M, Aref S, Fouda M, El-Sharawy S, “ Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia” Leuk Lymphoma, vol 45, No 10, pp 2029-35, Oct 2004.
10. Aref S, Mabed M, Selim T, Goda T, Khafagy N,”Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia” Hematology, vol 9, No. 5-6, pp 351-6, Oct-Dec 2004.
11. Aref S, Mabed M, Zalata K, Sakrana M, El Askalany H, “The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome” Leuk Lymphoma, vol 45, No. 3, pp 499-506, Mar 2004.
12. Aref S, El-Sherbiny M, Mabed M, Menessy A, El-Refaei M, “Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion” Hematology, vol. 8, No. 6, pp 385-91, Dec 2003.
13. S. Aref, M Fouda, E. El-Dosoky, A. Menessy, M Mabed, “C-Myc Oncogene and Cdc25A Cell Activating Phosphatase Expression in Non-Hodgkin’s Lymphoma” Hematology, Vol 8, No. 3, pp 183-190, 2003.
14. S.Aref, M.Mabed, M Sakarana, et al, “Soluble Hepatocyte Growth Factor (sHGF) and Vascular Endothelial Growth Factor (sVEGF) in Adult Acute Myeloid Leukemia: Relationship to Disease Characteristics” Hematology vol 7, No.5, pp. 273-279, 2002.
15. Valrie Herve, Mohamed Mabed, Vernique Laithier et al, “Evidence that a transient enhancement of endogenous hematopoiesis contributes significantly to the favorable outcome following interleukin-1 pretreatment and allogeneic bone marrow transplantation” Transplantation, vol 61 pp 673-676, 1996
16. Tiberghein P, Laithier V, Mabed M, et al, “ Interleukin-1 Administration before lethal irradiation and allogeneic bone marrow transplantation: early transient increase of peripheral granulocytes and successful engraftment with accelerated leukocyte, erythrocyte and platelet recovery” Blood, vol 81 pp 1933-1939, 1993